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Abstract 31 
Background The absence of economic evidence hinders current reforms of hospital based 32 
mental health systems in Central and Eastern Europe. We aimed to assess the cost-33 
effectiveness of care for people with chronic psychoses in psychiatric hospitals compared to 34 
discharging patients to the community in the Czech Republic. 35 
Methods We conducted a prospective study of people with chronic psychotic disorders and 36 
evaluated the impact associated with discharge into community services as compared to not 37 
discharging people from psychiatric hospitals at baseline in the Czech Republic. We 38 
measured utilization of services, health related quality of life, met and unmet needs, and 39 
global functioning using an adapted Client Services Receipt Inventory (CSRI), EQ-5D-5L, 40 
Camberwell Assessment of Need (CAN) and General Assessment of Functioning (GAF). 41 
Adjusting for baseline differences between the two groups, we assessed differences in 42 
societal costs in Euros (€) and QALYs over a year-long follow-up which we then used to 43 
estimate the incremental cost-effectiveness ratio (ICER). We conducted multiple sensitivity 44 
analyses to assess the robustness of our results. 45 
Outcomes In our base case scenario, we included 115 patients who were either inpatient or 46 
community services users at the baseline. The two groups were very similar in terms of their 47 
observed characteristics. The annual QALY was 0.77 and 0.80 in the group discharged to the 48 
community at the baseline compared to not being discharged (difference 0.03 95% 49 
confidence interval -0.04 to 0.1), but costs were €8,503 compared to €16,425 (difference 50 
€7,922, 95% confidence interval 4,371 to 11,472) such that the ICER reached over 250,000 € 51 
per QALY. This is considerably above levels that are conventionally considered to be cost-52 
effective and the estimated probability that discharge to the community was cost-effective 53 
was very high. None of the sensitivity analyses changed these results qualitatively. 54 
Interpretation This study provides economic evidence for deinstitutionalization by showing 55 
that discharge to community care is cost-effective when compared to care in psychiatric 56 
hospitals in the Czech Republic. Thus, it adds to the human rights- and clinical- based 57 
arguments for mental health care reforms in Central and Eastern Europe.  58 
Funding 59 
Ministry of Education, Youth and Sports of the Czech Republic; EEA and Norway Grants 60 
 61 
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 67 
Background 68 
Schizophrenia, schizoaffective disorder and other forms of psychosis are associated with 69 
considerable disability. Schizophrenia alone is currently ranked 11th in terms of years lived 70 
with disability (YLD) worldwide1. Psychotic disorders are also associated with high societal 71 
costs both in terms of health care costs and productivity losses. A recent systematic review by 72 
Jin and Mosweu2 reported that, in absolute terms, yearly societal costs for schizophrenia 73 
ranged from US$ 5,818 per patient in Thailand to US$ 94,587 in Norway or as share of the GDP 74 
per capita, from 37% in Switzerland to 214% in the UK.  75 
None of the studies included in this review, however, came from Central and Eastern Europe 76 
(CEE) where mental health care for people with severe mental illnesses is still predominantly 77 
provided in large psychiatric hospitals with limited community-based alternatives. In the 78 
Czech Republic, for example, people with schizophrenia are in many cases hospitalized for 5, 79 
10 or even 20 years and there are currently more than 8000 psychiatric beds for adults3,4.  80 
Historically, this resembles the psychiatric care systems in countries such as England or Finland 81 
which have since successfully undergone a process of deinstitutionalisation. In CEE, to date 82 
such reforms have been proposed but mostly remain in the realms of rhetoric or aspirations5. 83 
Research has demonstrated that deinstitutionalization is of benefit to people with severe 84 
mental illness and does not bring about serious negative consequences such as increasing 85 
homelessness or criminality6-8. Also, studies in a number of European countries have shown 86 
that care in the community is not more expensive than care in psychiatric hospitals when both, 87 
costs and outcomes of care, were considered9,10. Economic evaluations have played a 88 
prominent role in the deinstitutionalization processes in England and other countries, both in 89 
terms of providing an impetus for this policy and assisting in its success by means of regular 90 
monitoring of its impact10-13.  91 
In the last 25 years, almost no full economic evaluation of complex interventions for people 92 
with severe mental illnesses in CEE was published, which presents a challenge to efforts to 93 
reform or improve mental health care systems in the region5. Therefore, we aimed to generate 94 
such evidence in the context of the current mental health care reforms in the Czech Republic 95 
both to inform decision making in this country and as a prelude to further research and 96 
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deliberations on deinstitutionalising in the wider CEE region. To that end, we compared the 97 
quality of life and societal costs among people with psychosis who had been receiving care in 98 
psychiatric hospitals for at least 3 months with patients who had been discharged to the 99 
community care in the Czech Republic over a period of a year.  100 
Methods 101 
Study design and comparators 102 
We conducted a prospective study of people with chronic psychotic disorders in the Czech 103 
Republic. In order to approximate the impact of deinstitutionalisation on the cost-104 
effectiveness of care, we sought to assess what difference it would have made on average if 105 
patients who were long-term psychiatric inpatients (and may eventually be discharged 106 
according to current practice) had instead been discharged to receive community care at the 107 
start of our study (with the risk of being readmitted at a later stage). In our base case analysis 108 
we took  societal perspective with respect to measuring costs and a patient perspective with 109 
respect to accounting for health outcomes because this was thought to be the most relevant 110 
to decision makers. We evaluated these treatment strategies over one year which 111 
corresponds to the time horizon over which mental health care services are financed in the 112 
Czech Republic. We obtained an ethical approval for this study from both the ethical 113 
committee of the Prague Psychiatric Centre (currently the National Institute of Mental Health, 114 
Czech Republic) and the ethical committee of Psychiatric hospital Bohnice, Prague, Czech 115 
Republic. 116 
Participants and data collection 117 
For the purposes of this study we combined two separate samples: (1) Patients who were 118 
under inpatient psychiatric care were drawn from the SUPR project, a broader study aimed at 119 
monitoring the current standard of rehabilitative care on long-term wards with a particular 120 
focus on implementation of psychosocial rehabilitation principles and interventions on those 121 
units14. For this project, we invited all 17 Czech psychiatric hospitals to participate and, if they 122 
consented, asked them to select one or more wards primarily focused on providing care for 123 
chronic inpatients with psychosis from which study participants could be recruited; (2) 124 
Focussing on multidisciplinary community teams which predominately cared for people with 125 
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severe mental illness, we chose eight providers of such care from six (out of a total of 14) 126 
Czech administrative regions in an informal attempt to sample services representative in 127 
terms of the structure of mental health care and socio-cultural makeup of the Czech Republic. 128 
We contacted potentially eligible participants among the respective providers in random 129 
order until at least 17 patients per provider consented to participate in the study. 130 
To be included in the study, patients in both samples had to be of working age (i.e. between 131 
18 and 64), had to have been given any diagnosis of non-affective psychosis as defined by the 132 
ICD-10 codes F20 to F29, and had to have been in contact with mental health services for at 133 
least three months prior to data collection. The cognitive function of patients in the inpatient 134 
cohort had to exceed 17 points on the Montreal Cognitive Assessment screening test15 135 
whereas we assumed that the patients living in the community were of sufficient cognitively 136 
ability if they were thought to be able to give informed consent to study participation. After 137 
data collection, for our base case analysis we further restricted the community sample to 138 
people who had been discharged within less than a year prior to baseline so that our 139 
community sample reflected more closely the treatment strategy of interest, i.e. discharge to 140 
the community at baseline. We assessed all participants at baseline and then followed them 141 
up for a year at approximately 4 month intervals. 142 
Measure of effectiveness 143 
We used the EQ-5D-5L, a self-administered instrument consisting of five dimensions, to assess 144 
respondents’ health related quality of life at each assessment. Its predecessor, the three level 145 
EQ-5D-3L, has been extensively used as an outcome measure in health economic evaluations, 146 
particularly in the United Kingdom16,17,18. The five level version of this instrument was 147 
developed to improve the sensitivity of this previous three level version, and has been 148 
demonstrated to improve instruments’ discriminatory power 16,19. Although the EQ-5D 149 
descriptive system should be used with caution when measuring the impact of psychosis 20,21, 150 
its value for cost-effectiveness studies in mental health has been well demonstrated 22. Each 151 
of the health states measured by the EQ-5D-5L has been assigned a preference-based value, 152 
known as utility score, that summarises how good or bad each of the health states is on scale 153 
anchored by 1 corresponding to full health and 0 corresponding to a state equivalent to 154 
death23. Multiplying this utility score by the length of time spent in these health states yields 155 
quality adjusted life years (QALYs) which is a popular measure of health benefit in health 156 
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economic evaluation because it enables comparison of cost-effectiveness across disease 157 
areas24. We chose the UK tariffs to value health states because no Czech EQ-5D-5L tariffs are 158 
available and we deemed UK tariffs to be internationally the most influential24. We used the 159 
standard area under the curve method to calculate QALYs25.  160 
As part of the study, two further instruments were measured: First, respondents were 161 
interviewed by a person belonging to the staff of the mental health care facility that was 162 
trained to administer the Global Assessment of Functioning (GAF) before the beginning of data 163 
collection. The GAF is a rating scale ranging from 0 to 100 reflecting the global impression of 164 
an individual’s social, occupation and psychological function and is thought to have good 165 
psychometric properties for a brief instrument after appropriate training in its use26. We did 166 
not use GAF scores as a measure of treatment benefit because professionals in psychiatric 167 
hospitals who administered this instrument over the course of the follow-up were often 168 
different from those assessing GAF at the baseline and had thus not been trained in its use. 169 
Second, we assessed clinical and social needs and the degree to which they were met with the 170 
Camberwell Assessment of Needs (CAN), a tool developed both for use in clinical practice and 171 
research27. We used a 22-item version of the instrument which is filled by both health care 172 
professional and user. All the professionals who worked on collecting CAN data for this study 173 
had been trained in using this instrument at baseline but again this was not always the case 174 
over the follow-up. For this reason and due to the fact that only 11 post-baseline 175 
measurements were collected in the hospital cohort, we also chose not analyse CAN follow-176 
up ratings. 177 
Estimating service use and costs 178 
For the purposes of this study we adapted the commonly used Client Service Receipt Inventory 179 
(CSRI) to identify and measure resource use from a societal perspective in a Czech context 180 
among patients treated for psychosis and calculated unit costs thereof (see Appendix 1 for 181 
details). In short, this involved measuring and costing the use of mental health care services 182 
(i.e. psychiatric inpatient, outpatient use), non-healthcare services (i.e. criminal justice costs 183 
and community-based care which fall under social care in the Czech Republic) and productivity 184 
losses (both to the person with psychosis and their carer). We also collected data on 185 
medication use through the CSRI, but this information was not reliable enough for costing 186 
purposes in the community sample, so we excluded medication costs in our analysis. However, 187 
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good quality data on the medication costs was routinely collected on inpatient wards which 188 
gave us an idea of the magnitude of the potential difference between the two groups. We 189 
converted all costs in the study to 2016 Euros and, given the time horizon of the study, we 190 
discounted neither costs nor effects. Since the CSRI asked for the amount of service use over 191 
the month or three months preceding each interview, we linearly inflated the data to cover 192 
the entire 4-month period between interviews. 193 
Cost-effectiveness analysis 194 
We divided differences in costs over the follow-up period between the two groups by 195 
differences in QALYs to estimate the incremental cost-effectiveness ratio (ICER), a commonly 196 
used summary measure of cost-effectiveness. Unless, one of the treatments is both less costly 197 
and more effective, to be able to judge whether a treatment is cost-effective, it is necessary 198 
to put the ICER in relation to a so-called cost-effectiveness threshold, which has either been 199 
regarded to be the willingness to pay for health improvements by the decision maker or what 200 
health benefit could be generated if investments were made in a different health intervention, 201 
the so-called opportunity cost28. There is no official cost-effectiveness threshold in the Czech 202 
Republic (and many other countries), but two approaches have been proposed in the 203 
literature to provide some indication regarding their magnitude. The World Health 204 
Organisation suggests that an intervention could be cost-effective if the ICER is lower than one 205 
to three times a country’s GPD per capita (in 2016, approximately €17,000 to €50,000 in the 206 
Czech Republic), whereas a more recent approach by Woods et al. implies a threshold 207 
between approximately €8,000 and €22,00028-30. We illustrate the uncertainty surrounding 208 
these cost-effectiveness estimates graphically using two approaches. First, we produce a cost-209 
effectiveness plane (CEP), i.e. a diagram with difference in QALYs on the horizontal axis and 210 
difference in costs on the vertical axis displaying the central cost-effectiveness estimate and 211 
the uncertainty in terms of these two dimensions31. Second, we calculate the cost-212 
effectiveness acceptability curve (CEAC) which, in this case, shows the estimated probability 213 
that discharge to the community is cost-effective given the sampling uncertainty32. 214 
Potential confounders  215 
Particularly in observational studies, it is possible that the treatment groups of interest are 216 
not comparable because of factors that differ between them which are also causally 217 
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associated with the outcomes of interest. More specifically, in the context of this study, we 218 
had two concerns: (a) people who were in hospital at baseline could be more unwell than 219 
those in the community and this imbalance required reliance on a statistical model to adjust 220 
for these differences; (b) It was possible that some subgroups of patients were only present 221 
in one cohort but not the other, i.e. there would be a so-called ‘lack of overlap’ in some 222 
variables, such that either extrapolation beyond the observed data would be required or it 223 
was necessary to restrict the eligibility criteria to the study further. For example, it was 224 
conceivable that patients with severe psychotic symptoms or problematic care needs would 225 
only be observed in the hospital sample because this is where adequate care could be 226 
provided for them. To reduce this potential bias, we therefore both checked whether there 227 
was sufficient overlap between the two groups in terms of selected variables that were 228 
measured in the samples and, if necessary, adjusted for these variables in the analysis (see 229 
Appendix 2 for our variable selection strategy). In our base case analysis, we chose to adjust 230 
for (i) baseline EQ-5D-5L utility score, (ii) the baseline GAF score, (iii) age, (iv) gender, (v) 231 
interaction term between the time since discharge from hospital and the community/hospital 232 
group indicator. 233 
Statistical analyses 234 
For all our analyses, we used a regression approach to address observed confounding. In our 235 
primary analysis, we used a seemingly unrelated regression (SUR) approach to incorporate 236 
potential correlation between costs and QALYs into our statistical model33. To account for 237 
missing data, we used a multiple imputation approach which assumes that data was missing 238 
at random (MAR), i.e. missingness was unrelated to the unobserved value conditioning on all 239 
other variables. In addition, we assumed that, once discharged, patients who were in hospital 240 
at baseline had costs of service use equivalent to the community cohort (see Appendix 2 for 241 
details). While it was not possible to do so in our SUR model, when analysing QALYs and cost 242 
data separately (as well as in other secondary analyses), we used cluster robust standard 243 
errors to allow for correlation of outcomes within care facilities and we used a fractional logit 244 
model to model QALYs and EQ-5D-5L utilities since, by definition, these are constrained to be 245 
smaller than 1 in this study. We used a negative binomial regression model to analyse 246 
differences in service use and a random effects logit model to estimate medication use. We 247 
performed all statistical analyses in Stata 1534. In line with expected mortality in this 248 
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population, one of the study participants died during the study follow-up, however, we 249 
considered our sample size too small to warrant the attempt to statistically model survival 250 
differences between groups using non-standard methods that adequately account for such 251 
rare events35,36. Instead, for simplicity, we treated the data following the death of this patient 252 
as missing. 253 
Sensitivity analyses 254 
To assess the sensitivity of the results, we first investigated whether the degree to which we 255 
restricted our community sample had any impact by increasing the maximum time between 256 
hospital discharge and baseline to two years and to five years. Second, based on evidence by 257 
Tulloch et al.37 we used both a quadratic and a linear interaction factor between community 258 
care and time since discharge. Third, in addition to the aforementioned potential confounders, 259 
we included five CAN items in the analysis, namely whether the patient had any needs in terms 260 
of self-care (item 4), psychotic symptoms (item 7), safety to self (item 10) or any substance 261 
abuse problems (items 12 and 13 combined) (see appendix 2 for our rationale behind this 262 
choice). Fourth, data could be missing not at random (MNAR) rather than MAR, i.e. 263 
missingness could be associated with the unobserved value after conditioning on other 264 
variables. Hence, we investigated the impact of increasing and decreasing the utility score of 265 
time points in which there was missing data by approximately half a baseline standard 266 
deviation, i.e. ±0.1. Fifth, we excluded patients who did not fulfil the above-mentioned overlap 267 
requirement instead of extrapolating results based on the statistical model. Finally, we 268 
calculated the cost-effectiveness of the intervention from a government rather than a societal 269 
perspective, i.e. we excluded informal care costs and productivity losses, because this may be 270 
of relevance to some decision makers. 271 
Results 272 
Participants and descriptive statistics 273 
Overall, 115 patients were included in our base case analysis (see Figure 1). More participants 274 
were inpatients at baseline services (n=80, 70%) and more were male (n=68, 59%). For further 275 
sociodemographic characteristics see Table 1. Appendix Table A.3.1 shows that, on average, 276 
patients who agreed to participate in the community sample had longer length of contact with 277 
mental health services and were less likely to be single compared to those who declined to 278 
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participate. Appendix Figure A.3.1 shows that the rate of missingness for the potential 279 
confounders and outcome measures was markedly higher in patients who were inpatients at 280 
baseline and Appendix 2 discusses some of the reasons behind this. Figures A.3.2 and A.3.3 in 281 
the appendix show that the two groups were well balanced in terms of most potential 282 
confounders, however, self-care needs were somewhat more common among those who 283 
were inpatients at baseline and problems with psychotic symptoms were less common. There 284 
was some lack of overlap at the upper end of the distribution of GAF scores and at the lower 285 
end of the distribution of EQ-5D-5L utility scores. Use of antipsychotics at baseline and over 286 
the study follow-up were broadly comparable across the two groups but those who received 287 
hospital care at baseline were more likely to use multiple classes of antipsychotics and 2nd 288 
generation antipsychotics over the study follow-up (see appendix figure A.3.4). 289 
Costs, QALYs and cost-effectiveness 290 
As shown in Figure 3(b), societal costs over the study follow-up were consistently significantly 291 
higher in patients who were on a psychiatric ward at baseline, leading to an overall difference 292 
in costs of €7,922 (95% confidence interval (CI) 4497 to 11346). This difference was almost 293 
exclusively caused by the cost of inpatient care itself such that the decrease in costs among 294 
people who had not been discharged to the community at baseline mirrors the fact that by 295 
the end of follow-up approximately half of this group had been discharged (see Figure A.3.5). 296 
Costs of social care were somewhat higher in the community cohort and productivity losses 297 
slightly lower but, compared to differences in terms of health care costs between the groups 298 
driven by the high cost of inpatient care itself, these were insubstantial (see Figure 2). Patients 299 
who were in hospital at baseline had a 0.03 (95% CI -0.04 to 0.1) higher QALY over the follow-300 
up but as shown in Figure 3 (a), EQ-5D-5L utility scores remained relatively stable in both arms. 301 
The cost-effectiveness plane in Appendix Figure A.3.6 illustrates the joint sampling uncertainty 302 
with respect to cost and QALY differences and Table A.3.2 shows the full regression results of 303 
the base case analysis. With an ICER of €256,855 per QALY, the QALY gain was not sufficiently 304 
high to offset the large difference in costs between the group such that, even at the highest 305 
of the thresholds mentioned above (€50,000 per QALY) continued inpatient care was not cost-306 
effective. In fact, the cost-effectiveness acceptability curve in Appendix Figure A.3.7 indicates 307 
that even at a willingness to pay as high as €100,000 per QALY the probability that discharge 308 
to the community is cost-effective remains above 75%. Table 2 shows that, quantitatively, the 309 
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ICER was significantly affected by assumptions regarding the EQ-5D-5L missingness 310 
mechanism and how time since discharge was adjusted for in the model. However, even in 311 
the scenario most favourable not discharging patients at baseline we obtained an ICER of 312 
approximately €110,000 and the lowest probability that discharge to the community was cost-313 
effective was estimated to be 97% such that, qualitatively, the results did not change in any 314 
of the sensitivity analyses. 315 
 316 
Discussion 317 
This is the first study to provide economic evidence for the mental health care reform in the 318 
Czech Republic and could potentially act as a prototype for assessing similar reforms in other 319 
countries of CEE. Similar to previous studies, our results show that inpatient care for people 320 
with chronic psychosis is costly compared to the care in the community and these differences 321 
do not appear to be offset by savings elsewhere. Moreover, the difference in annual costs per 322 
patient of €7,922 dwarfed the 0.03 gain in QALYs. The high ICER did not appear to be a result 323 
of substandard antipsychotic treatments on psychiatric wards and were robust in our 324 
sensitivity analyses. In addition, patients who were discharged within less than one year and 325 
inpatients were much more similar in terms of their observed characteristics at baseline than 326 
we expected. This supported the comparability between the two groups and suggests that, if 327 
appropriately carried out, deinstitutionalisation may be feasible for a large proportion of the 328 
current inpatient population. Just like in other countries which have undergone the process 329 
of deinstitutionalisation, we do not believe that the results imply that there is no role for 330 
inpatient care but that shifting investments towards community care and providing time-331 
restricted inpatient care is likely to give better value for money than long-term psychiatric 332 
hospitalisations. This argument adds to the human rights arguments based on the CRPD and 333 
especially on its article 19 emphasizing a right to live independently and in the community4,38, 334 
and clinical arguments based on long-term favourable outcomes of deinstitutionalized 335 
patients in other countries of the world6,7.  336 
In terms of the scope of the study, the construction of the Czech version of the CSRI, 337 
calculation of unit costs, review of health service and epidemiological data and building 338 
partnership with providers of mental health care in the Czech Republic have been pioneering 339 
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and we were able to capture a broad range of cost-drivers and verify the accuracy of data in 340 
many cases. For example, although consumption of care was not independently assessed (e.g. 341 
by health insurance companies), where possible, we were able to cross-check CSRI data 342 
against the records of participating facilities to improve the accuracy of health and social care 343 
use data. At the same time, we did not account for the impact of discharge to the community 344 
on people other than the patient (e.g. family or partners providing care to the patient) or 345 
measure costs of physical health care, housing and pharmaceuticals. Participants were 346 
interviewed by a staff member of a mental health care facility upon completion of CSRI. This 347 
might have introduced some bias, as participants may have been hesitant to disclose sensitive 348 
information, such as contact with the system of criminal justice. In practice, we were also 349 
unable to compare the groups in terms of any measure of effectiveness other than QALYs 350 
derived from EQ-5D-5L. In addition, in this study we only followed up our participants for a 351 
year and we would think that the comparative advantage of discharge to the community care 352 
are likely to extend beyond this period thereby potentially improving cost-effectiveness 353 
further. Perhaps more importantly, one should keep in mind that we did not evaluate the 354 
impact of the reform directly, but we effectively estimated the cost-effectiveness of post-355 
reform care practices compared with the current care practice once the necessary 356 
infrastructure and care professionals in the community are in place, i.e. leaving aside setup 357 
costs that are likely to be incurred. In addition, in practice, both systems, the old hospital-358 
based and the new community-based one, will have to be run simultaneously for some time.  359 
Several aspects relating to the study design are also relevant to the interpretation of the 360 
results and to informing the conduct of future studies of this kind. Although attempts were 361 
made to recruit patients from services that captured the regional variations in terms of the 362 
structure of mental health care and socio-cultural background of the Czech Republic, we only 363 
had limited evidence on whether institutions or participants who declined to participate 364 
systematically differed from the one’s that would be impacted by the health care reforms and 365 
whether this may have led to recruitment bias. Rather than restricting our sample and relying 366 
on the correct specification of our statistical model, it would have been preferable to recruit 367 
people at the time of discharge to community services. Finally, as in every observational study, 368 
although we showed that there were no large differences between the two patient 369 
populations in terms of socio-demographic characteristics, health-related quality of life and 370 
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functioning, bias may have arisen due to the presence of unobserved confounders and the 371 
small sample size of the study limited our ability to adjust for confounding. 372 
 373 
Conclusions 374 
We demonstrated that in the Czech Republic, community-based care for people with chronic 375 
psychotic disorders is far less costly than care in psychiatric hospitals. We believe that this is 376 
yet another argument for pursuing deinstitutionalization in the Czech Republic. The results of 377 
this study add to the current modest evidence on the economics of deinstitutionalization10,40 378 
and, while one should be cautious in extrapolating the evidence to other CEE countries, the 379 
results suggest that deinstitutionalisation may not just be cost-effective in Western countries 380 
but also in a mental health care system that is much more similar to those in this region where 381 
other evidence is currently lacking5 and where there is a lack of evaluative culture41. We 382 
believe that the economic evidence from the present study should be complemented with 383 
additional studies looking into economic consequences of the deinstitutionalization which has 384 
been proposed in the region. For example, similar to studies conducted in England, Italy, and 385 
Germany10,42, economic models of shifting the care from hospitals to communities as well as 386 
analyses of differences in costs across providers and regions would be useful. Before 387 
implementing this policy, decision makers also need to consider how to finance it. The Czech 388 
Republic utilized European Structural and Investment Funds to cover the costs of the first 389 
phase of the transition period and this funding opportunity may be open to other EU countries 390 
in the region, whereas non-EU countries in CEE may be able to benefit from other sources, 391 
such as the cooperation with Swiss Agency for Development and Cooperation. In addition, it 392 
would be undesirable if savings in one sector (e.g. health care) would be possible because of 393 
partially shifting the costs to another sector (e.g. social care) without appropriate rebalancing 394 
of budgets. Following deinstitutionalization, it would be valuable to follow up people in the 395 
community to monitor their services use and clinical outcomes in order to assess phenomena 396 
which have been associated with deinstitutionalization, such as decrease in (post-discharge) 397 
suicides43 and mortality44 among patients, increase in revolving door45, 398 
transinstitutionalization46, and satisfaction and quality of life of patients6. The studies of this 399 
kind should inform the decision making to ensure that the proposed reforms are economically 400 
sound, beneficial to patients and sustainable. 401 
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Tables and figures 534 
Table 1: Baseline patient characteristics in the base case analysis (N=115) 535 
Care location at baseline Community 
(N=35) 
 Hospital (N=80)  
Patient characteristic\Summary 
statistic 
N† %*,† N (%*)† %*,† 
Gender Male 21 60 47 59 
 Female 14 40 33 41 
 Missing 0 0 0 0 
Nationality Czech 34 97 74 95 
 Other 1 3 4 5 
 Missing 0 0 2 3 
Marital status Single 19 54 39 62 
 Unmarried 
with a partner 5 14 6 10 
 Married 1 3 3 5 
 Divorced 10 29 14 22 
 Widowed 0 0 1 2 
 Missing 0 0 17 21 
Highest 
educational 
attainment 
Elementary 
3 9 26 33 
 Lower 
secondary 20 57 30 38 
 Higher 
secondary 8 23 17 22 
 College 
education 4 11 5 6 
 Missing 0 0 2 3 
Age (in years) Mean (SD) 41 11 42 11 
 Missing 0 0 1 1 
Years of contact 
with mental 
health services 
Mean (SD) 2.5 2.7 2.1 2.2 
Missing 
0 0 14 18 
Days since 
discharge 
Mean (SD) 
194 104 n/a n/a 
*For categories other that ‘Missing’ the denominator for the percentages is the number of observations 536 
without missing data whereas for the ‘Missing’ category the percentage of missing data as a share of the 537 
whole sample is shown 538 
† unless otherwise specified in the second column 539 
SD: standard deviation 540 
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Figure 1: Study flow-chart 542 
Hospital 
 
Care location at baseline Community 
18 Total number of providers 
in the Czech Republic 
c.20 
   
18 Providers invited for 
participation in the study 
8 
   
11 (13 
wards) 
Providers who agreed to 
participate in the study 
8 
   
Unknown Patients considered as 
potentially eligible for the 
study  
277 
   
86 Patients who consented to 
participate in the study 
138* 
   
80† Patients included in the 
base case analysis 
35** 
 543 
* Reasons for non-participation: not in a good health (N=29), no interest in research (N=29), hospitalised 544 
(N=26), concerns about confidentiality of the study (N=22), no longer seen by service (N=13), unable to be 545 
reached (N=9), length/frequency of interviews (N=7), lack of cooperation (N=4) (see Appendix Table A.3.1 546 
for comparison of characteristics between participants and non-participatns) 547 
** Reason for exclusion: missing data on time from last hospitalisation (N=26), more than 1 year since 548 
discharge from psychiatric hospital (N=75) 549 
† Reason for exclusion: missing all follow-up cost and EQ-5D-5L date (N=6) 550 
  551 
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Figure 2: Unadjusted costs by category over the 12-month follow-up by treatment group (base case 552 
analysis) 553 
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Figure 3: Development of unadjusted (a) EQ-5D-5L utility scores and (b) societal costs over the 557 
study follow-up (base case analysis) 558 
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Table 2: Difference in costs, quality adjusted life years (QALYs) and cost-effectiveness by analysis scenario 561 
 Difference in costs 
(Not discharged at 
baseline-discharge to 
community at 
baseline) 
Difference in QALYs (Not 
discharged at baseline-
discharge to community at 
baseline) 
Incremental cost-
effectiveness 
ratio (ICER) 
Probability of a discharge to 
the community at baseline 
being cost-effective at a 
threshold of €50,000/QALY 
Scenario Mean 95% 
Confidence 
Interval  
Mean 95% Confidence 
Interval  
Base case 7922 4497 11346 0.03 -0.04 0.1 256855 100 
Include patients up to 2 years 
after discharge  8684 6096 11272 0.04 -0.01 0.09 197573 100 
Include patients up to 5 years 
after discharge 9580 7571 11588 0.06 0.02 0.1 157477 100 
Adding quadratic interaction 
term 6017 698 11336 -0.02 -0.12 0.09 -398752 97 
Adjusting for CAN items 7774 4234 11314 0.03 -0.04 0.1 263908 100 
Increasing missing EQ-5D-5L 
by 0.1 7922 4497 11346 0.07 0 0.13 115764 97 
Decreasing missing EQ-5D-5L 
by 0.1 7922 4497 11346 -0.01 -0.08 0.06 -1174035 100 
Removing non-overlapping 
observations 7867 4237 11497 0.03 -0.04 0.1 268784 100 
Government perspective 7685 4370 11000 0.03 -0.03 0.1 233172 100 
562 
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Research in context 563 
Evidence before this study 564 
Economic evaluations have been widely used to support deinstitutionalization in a number of European 565 
countries. Studies that assessed both, costs and outcomes of mental health care for people with chronic severe 566 
mental illnesses, suggested that community care may be more cost-effective than long-stay hospital care. 567 
Mental health care reforms in the region of Central and Eastern Europe has remained largely unimplemented 568 
and the economic evidence to inform decision making there is almost completely missing. 569 
Added value of this study 570 
This study demonstrates that deinstitutionalization of psychiatric hospitals in the Czech Republic is a reform  571 
which is not only in line with EU and WHO policy recommendations, but which is also cost-effective. Although, 572 
in our sample, the QALY gain was slightly lower among patients who were discharged to community services 573 
when compared to those who stayed inpatient, the annual costs were much disproportionately higher in the 574 
inpatient group. 575 
Implications of all the available evidence 576 
The available evidence, which is now based not only on human rights and clinical but also on the economic 577 
argument, supports deinstitutionalization in the region of Central and Eastern Europe. Individual countries in 578 
the region should look for resources to fund transitional period which might temporarily incur higher costs 579 
associated with setting up new services, maintaining both, the old and the new mental health care system, and 580 
accommodating needs of deinstitutionalized patients. In order to achieve an optimal balance between costs 581 
and outcomes of mental health care in the region, future studies should model various scenarios of mental 582 
health care reforms in individual countries. 583 
 584 
 585 
